MLTX SECURITIES ALERT: BFA Law Notifies MoonLake Immunotherapeutics Shareholders of Pending Securities Fraud Class Action and Upcoming December 15 Deadline

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a deadline for investors to act by December 15, 2025 [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [4]. Allegations and Clinical Data - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients and differentiation from competitors [5]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [6]. Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].